| Literature DB >> 30619865 |
Dimitar Tasev1, Laura Dekker-Vroling2, Michiel van Wijhe1, Henk J Broxterman2, Pieter Koolwijk1, Victor W M van Hinsbergh1.
Abstract
Vascular homeostasis and regeneration in ischemic tissue relies on intrinsic competence of the tissue to rapidly recruit endothelial cells for vascularization. The mononuclear cell (MNC) fraction of blood contains circulating progenitors committed to endothelial lineage. These progenitors give rise to endothelial colony-forming cells (ECFCs) that actively participate in neovascularization of ischemic tissue. To evaluate if the initial clonal outgrowth of ECFCs from cord (CB) and peripheral blood (PB) was stimulated by hypoxic conditions, MNCs obtained from CB and PB were subjected to 20 and 1% O2 cell culture conditions. Clonal outgrowth was followed during a 30 day incubation period. Hypoxia impaired the initial outgrowth of ECFC colonies from CB and also reduced their number that were developing from PB MNCs. Three days of oxygenation (20% O2) prior to hypoxia could overcome the initial CB-ECFC outgrowth. Once proliferating and subcultured the CB-ECFCs growth was only modestly affected by hypoxia; proliferation of PB-ECFCs was reduced to a similar extent (18-30% reduction). Early passages of subcultured CB- and PB-ECFCs contained only viable cells and few if any senescent cells. Tube formation by subcultured PB-ECFCs was also markedly inhibited by continuous exposure to 1% O2. Gene expression profiles point to regulation of the cell cycle and metabolism as major altered gene clusters. Finally we discuss our counterintuitive observations in the context of the important role that hypoxia has in promoting neovascularization.Entities:
Keywords: ECFCs; angiogenesis; colony growth; hypoxia; proliferation; tissue repair
Year: 2018 PMID: 30619865 PMCID: PMC6306419 DOI: 10.3389/fmed.2018.00356
Source DB: PubMed Journal: Front Med (Lausanne) ISSN: 2296-858X
Figure 1Inhibition of clonal outgrowth of ECFCs from cord and peripheral blood MNCs by hypoxia. (A,B) Primary colony of CB-ECFCs isolated at 1% of oxygen. Bars are 500 μm (A) and 100 μm (B), respectively. (C) Staining of VE-cadherin (green), f-actin (red), and nuclei (DAPI) of a primary colony of CB-ECFCs. Note two dividing cells in the middle top part. Bar = 100 μm (D) Enumeration of outgrowth colonies from umbilical cord blood-derived MNCs at 20 and 1% O2 expressed as average number ± SEM (n = 14) of counted colonies per donor. Statistical significance was determined by Wilcoxon matched-pairs signed rank test; ***p < 0.005. (E) Enumeration of outgrowth colonies from peripheral blood-derived MNCs at 20 and 1% O2 expressed as average number ± SEM (n = 9) of counted colonies per donor. Statistical significance was determined by Wilcoxon matched-pairs signed rank test; **p < 0.01.
Figure 2Proliferation of subcultured CB and PB-ECFCs at various oxygen concentrations. The effect of oxygen concentration (20, 5, 2, and 1%) in the absence (A,C) or presence of 10 ng/ml TNFα (B,D) on the proliferation rate of subcultured CB-ECFCs, expressed as mean number of cells/cm2 of 3 CB-ECFC and 3 PB-ECFC isolations of different donors ± SEM, is shown.
Figure 3Prior exposure to 20% O2 restores the induction of ECFC colony formation in 1% O2. The graph depicts enumeration of ECFC colony outgrowth from umbilical cord blood-derived MNCs. (A) The freshly isolated CB-MNC fractions of three donors were seeded and exposed for varying periods (0–96 h) to ambient oxygen (20% O2) and subsequently transferred to 1% O2 atmosphere for additional culture (B) ECFC colony outgrowth from umbilical cord blood-derived MNCs obtained from three different donors after 24, 48, 72, or 96 h exposure to 20% O2. Cells cultured only in 20% O2 (20%), or 1% O2 (0 h) served as controls. ECFC colonies were quantified when the colonies had become visible in the culture in 20% O2 and expressed as average number ± SEM (n = 3) of counted colonies. Statistical significance was determined by a One-way ANOVA with Bonferroni post-hoc test; *p < 0.05.
Figure 4Inhibition of tube-forming capacity of PB-ECFCs when cultured at 1% O2. PB-ECFCs obtained from different donors were serially expanded in medium supplemented with PL at 20 or 1% of oxygen for 7 days. The PB-ECFCs were then seeded on 3D fibrin matrices and the sprouting ability of cells in fibrin matrices was then assessed after stimulation with the combination of 10 ng/ml TNFα and 25 ng/ml VEGF at 20% O2 (phase contrast picture A) or 1% O2 (phase contrast picture B) for a period of 96 h (bar = 1,000 μm). Results represent the mean ± SEM (n = 7) of the length of tube-like structures of the donors (C) Statistical significance between two oxygen concentration conditions was determined by unpaired t-test; *p < 0.05).
Figure 5Venn diagram of genes upregulated of downregulated in control (A) and VEGF/TNFα-stimulated (B) PB-ECFCs.
Top (q < 0.05) 25 Up regulated genes by hypoxia (non-stimulated PB-ECFCs).
| PIK3R6 | 107,9 | phosphoinositide-3-kinase, regulatory subunit 6 |
| MIR210HG | 22,48 | MIR210 host gene (non-protein coding) |
| ANGPTL4 | 17,06 | angiopoietin-like 4 |
| GDF6 | 16,87 | growth differentiation factor 6 |
| SYTL2 | 16,32 | synaptotagmin-like 2 |
| PROM1 | 15,77 | prominin 1 |
| VEGFA | 12,62 | vascular endothelial growth factor A |
| ENO2 | 10,35 | enolase 2 (gamma, neuronal) |
| SLC2A1 | 10,02 | solute carrier family 2 (facilitated glucose transporter), member 1 |
| INHBA | 10 | inhibin, beta A |
| DNAH8 | 9,74 | dynein, axonemal, heavy chain 8 |
| ADM2 | 9,19 | adrenomedullin 2 |
| FBLN2 | 8,85 | fibulin 2 |
| STC2 | 8,82 | stanniocalcin 2 |
| ELN | 8,4 | Elastin |
| GALNTL2 | 7,58 | UDP-N-acetyl-alpha-D-galactosamine:polypeptide |
| N-acetylgalactosaminyltransferase-like 2 | ||
| PODN | 7,11 | Podocan |
| FER1L4 | 6,35 | fer-1-like 4 (C. elegans) pseudogene |
| ALDOC | 6,13 | aldolase C, fructose-bisphosphate |
| AK4 | 6 | adenylate kinase 4 |
| NPTX1 | 5,92 | neuronal pentraxin I |
| SDC2 | 5,38 | syndecan 2 |
| SMAD7 | 5,37 | SMAD family member 7 |
| TGFBI | 5,29 | transforming growth factor, beta-induced, 68 kDa |
| ALDH1L2 | 5,28 | aldehyde dehydrogenase 1 family, member L2 |
Top (q < 0.05) 17 down regulated genes by hypoxia (VT-stimulated PB-ECFCs).
| CCL8 | −23,88 | chemokine (C-C motif) ligand 8 |
| C3 | −5,96 | complement component 3 |
| IL1B | −4,88 | interleukin 1, beta |
| KYNU | −4,51 | kynureninase |
| EFNB2 | −3,95 | ephrin-B2 |
| PLK1 | −3,85 | polo-like kinase 1 |
| ADAMTS1 | −3,79 | ADAM metallopeptidase with thrombospondin type 1 motif, 1 |
| DLGAP5 | −3,02 | discs, large (Drosophila) homolog-associated protein 5 |
| CD200 | −3,02 | CD200 molecule |
| CHST1 | −2,95 | carbohydrate (keratan sulfate Gal-6) sulfotransferase 1 |
| BUB1B | −2,66 | budding uninhibited by benzimidazoles 1 homolog beta (yeast) |
| PAK6 | −2,66 | p21 protein (Cdc42/Rac)-activated kinase 6 |
| TNFRSF11B | −2,66 | tumor necrosis factor receptor superfamily, member 11b |
| TOP2A | −2,65 | topoisomerase (DNA) II alpha 170 kDa |
| BMX | −2,61 | BMX non-receptor tyrosine kinase |
| RRM2 | −2,56 | ribonucleotide reductase M2 |
| MKI67 | −2,44 | antigen identified by monoclonal antibody Ki-67 |
Figure 6Downregulation of cell cycle genes and upregulation of metabolic genes by hypoxia. Predicted protein-protein interactions show different protein clusters. Genes that were significantly differentially regulated (FDR < 5%) in hypoxia (A,C), down-regulated (B) or upregulated in hypoxia (D) were clustered based on protein-protein interactions. The nodes represent the proteins and a shared function of the proteins are shown as interconnecting lines. The genes were clustered based on the GO (0051301) cell division pathway (A,B) or the KEGG (01100) metabolic pathway; genes involved in these pathways are indicated in red.
Hypoxia pathway analysis.
| Metabolic pathways | Metabolic pathways | |||
| Cell cycle | Cell cycle | |||
| Glycolysis / Gluconeogenesis | Glycolysis / Gluconeogenesis | |||
| Renal cell carcinoma | Renal cell carcinoma | |||
| Glycine, serine and threonine metabolism | Glycine, serine and threonine metabolism | |||
| TGF-beta signaling pathway | TGF-beta signaling pathway | |||
| p53 signaling pathway | p53 signaling pathway | |||
| Purine metabolism | Purine metabolism | |||
| Pentose phosphate pathway | ||||
| Mucin type O-Glycan biosynthesis | ||||
| Cysteine and methionine metabolism | ||||
| Fructose and mannose metabolism | ||||
| Cytokine-cytokine receptor interaction | Cytokine-cytokine receptor interaction | |||
| mTOR signaling pathway | ||||
| Adipocytokine signaling pathway | Adipocytokine signaling pathway | |||
| Pathways in cancer | Pathways in cancer | |||
| ECM-receptor interaction | ||||
| Ribosome | Ribosome | |||
| PPAR signaling pathway | ||||
| Axon guidance | ||||
| Focal adhesion | ||||
The KEGG pathways involved in angiogenesis and metabolism with a p < 0.05 are show. Red is upregulated and green is downregulated.
Top (q < 0.05) 25 Up regulated genes by hypoxia (VT-stimulated PB-ECFCs).
| EGLN3 | 61,41 | egl nine homolog 3 (C. elegans) |
| NUPR1 | 13,83 | nuclear protein, transcriptional regulator, 1 |
| FABP3 | 12,52 | fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor) |
| PPARG | 9,30 | peroxisome proliferator-activated receptor gamma |
| TGFBI | 9,22 | transforming growth factor, beta-induced, 68kDa |
| DNER | 7,56 | delta/notch-like EGF repeat containing |
| SLC8A3 | 7,23 | solute carrier family 8 (sodium/calcium exchanger), member 3 |
| SYTL2 | 6,43 | synaptotagmin-like 2 |
| HIF3A | 6,38 | hypoxia inducible factor 3, alpha subunit |
| ANGPTL4 | 6,16 | angiopoietin-like 4 |
| COL25A1 | 5,05 | collagen, type XXV, alpha 1 |
| PHGDH | 4,95 | phosphoglycerate dehydrogenase |
| NDRG1 | 4,81 | N-myc downstream regulated 1 |
| ENO2 | 4,65 | enolase 2 (gamma, neuronal) |
| ADM2 | 4,65 | adrenomedullin 2 |
| CSPG5 | 4,48 | chondroitin sulfate proteoglycan 5 (neuroglycan C) |
| JDP2 | 4,39 | Jun dimerization protein 2 |
| GPNMB | 4,38 | glycoprotein (transmembrane) nmb |
| KLF4 | 4,28 | Kruppel-like factor 4 (gut) |
| VEGFA | 3,99 | vascular endothelial growth factor A |
| NPTX1 | 3,94 | neuronal pentraxin I |
| SLC2A1 | 3,88 | solute carrier family 2 (facilitated glucose transporter), member 1 |
| MEGF6 | 3,83 | multiple EGF-like-domains 6 |
| MN1 | 3,82 | meningioma (disrupted in balanced translocation) 1 |
| COL8A2 | 3,72 | collagen, type VIII, alpha 2 |
Top (q < 0.05) 25 Down regulated genes by hypoxia (non-stimulated PB-ECFCs).
| PRND | −22,49 | prion protein 2 (dublet) |
| APLNR | −18,14 | apelin receptor |
| GJA4 | −15,17 | gap junction protein, alpha 4, 37 kDa |
| INHBB | −6,37 | inhibin, beta B |
| AQP1 | −5,00 | aquaporin 1 (Colton blood group) |
| RPS17 | −4,88 | ribosomal protein S17 |
| RPS17L | −4,83 | ribosomal protein S17-like |
| CDC20 | −4,28 | cell division cycle 20 homolog (S. cerevisiae) |
| LYVE1 | −4,10 | lymphatic vessel endothelial hyaluronan receptor 1 |
| NUF2 | −4,02 | NUF2, NDC80 kinetochore complex component, homolog (S. cerevisiae) |
| HMMR | −3,74 | hyaluronan-mediated motility receptor (RHAMM) |
| NQO1 | −3,70 | NAD(P)H dehydrogenase, quinone 1 |
| UCP2 | −3,63 | uncoupling protein 2 (mitochondrial, proton carrier) |
| CKAP2L | −3,62 | cytoskeleton associated protein 2-like |
| BUB1B | −3,54 | budding uninhibited by benzimidazoles 1 homolog beta (yeast) |
| PAK6 | −3,54 | p21 protein (Cdc42/Rac)-activated kinase 6 |
| PLK1 | −3,52 | polo-like kinase 1 |
| ANLN | −3,28 | anillin, actin binding protein |
| KIF4A | −3,28 | kinesin family member 4A |
| SHCBP1 | −3,23 | SHC SH2-domain binding protein 1 |
| BIRC5 | −3,21 | baculoviral IAP repeat containing 5 |
| TPX2 | −3,16 | TPX2, microtubule-associated, homolog (Xenopus laevis) |
| SPAG5 | −3,11 | sperm associated antigen 5 |
| KIFC1 | −3,09 | kinesin family member C1 |
| CDCA8 | −3,09 | cell division cycle associated 8 |